|
1) Hida K, Wada J, Zhang H, et al. Identification of genes specifically expressed in the accumulated visceral adipose tissue of OLETF rats. J Lipid Res. 2000; 41: 1615-22
|
|
|
|
2) Eguchi J, Wada J, Hida K, et al. Identification of adipocyte adhesion molecule (ACAM), a novel CTX gene family, implicated in adipocyte matu-ration and development of obesity. Biochem J. 2005; 387: 343-53
|
|
|
|
|
3) Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A. 2005; 102: 10610-5
|
|
|
|
|
|
4) Kloting N, Berndt J, Kralisch S, et al. Vaspin gene expression in human adipose tissue: asso-ciation with obesity and type 2 diabetes. Biochem Biophys Res Commun. 2006; 339: 430-6
|
|
|
|
|
|
5) Youn BS, Kloting N, Kratzsch J, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes. 2008; 57: 372-7
|
|
|
|
|
|
6) Tan BK, Heutling D, Chen J, et al. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome con-comitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes. 2008; 57: 1501-7
|
|
|
|
|
|
7) Seeger J, Ziegelmeier M, Bachmann A, et al. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab. 2008; 93: 247-51
|
|
|
|
|
|
8) Suleymanoglu S, Tascilar E, Pirgon O, et al. Vaspin and its correlation with insulin sensitivity indices in obese children. Diabetes Res Clin Pract. 2009; 84: 325-8
|
|
|
|
|
|
9) Handisurya A, Riedl M, Vila G, et al. Serum vaspin concentrations in relation to insulin sensitivity following RYGB-induced weight loss. Obes Surg. 2009 Jun 9. [Epub ahead of print]
|
|
|
|
|
|
10) Aust G, Richter O, Rohm S, et al. Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis. 2009; 204: 262-6
|
|
|
|
|
|
11) Gulcelik NE, Karakaya J, Gedik A, et al. Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur J Endocrinol. 2009; 160: 65-70
|
|
|
|
|
|
12) Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med. 1996; 2: 800-3
|
|
|
|
|
|
13) Koulmanda M, Bhasin M, Hoffman L, et al. Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci U S A. 2008; 105: 16242-7
|
|
|
|
|
|
14) Dichtl W, Moraga F, Ares MP, et al. The carboxyl-terminal fragment of alpha1-antitrypsin is present in atherosclerotic plaques and regulates inflam-matory transcription factors in primary human monocytes. Mol Cell Biol Res Commun. 2000; 4: 50-61
|
|
|
|
|
|
15) Wada J. Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin Investig Drugs. 2008; 17: 327-33
|
|
|
|
|